MARKET

CCCC

CCCC

C4 Therapeutics, Inc.
NASDAQ
1.620
+0.080
+5.19%
Closed 19:40 04/28 EDT
OPEN
1.570
PREV CLOSE
1.540
HIGH
1.670
LOW
1.530
VOLUME
1.09M
TURNOVER
--
52 WEEK HIGH
7.66
52 WEEK LOW
1.085
MARKET CAP
115.00M
P/E (TTM)
-1.0671
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CCCC last week (0421-0425)?
Weekly Report · 1d ago
Weekly Report: what happened at CCCC last week (0414-0418)?
Weekly Report · 04/21 09:02
Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%
Simply Wall St · 04/18 11:12
C4 Therapeutics Board Member Bruce Downey Retires
TipRanks · 04/14 12:45
Weekly Report: what happened at CCCC last week (0407-0411)?
Weekly Report · 04/14 09:02
Weekly Report: what happened at CCCC last week (0331-0404)?
Weekly Report · 04/07 09:02
Weekly Report: what happened at CCCC last week (0324-0328)?
Weekly Report · 03/31 09:02
Weekly Report: what happened at CCCC last week (0317-0321)?
Weekly Report · 03/24 09:02
More
About CCCC
More
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Recently
Symbol
Price
%Change

Webull offers C4 Therapeutics Inc stock information, including NASDAQ: CCCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCCC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CCCC stock methods without spending real money on the virtual paper trading platform.